Basel, Switzerland
Basel, Switzerland

Time filter

Source Type

News Article | February 22, 2017
Site: www.eurekalert.org

New ways to convert carbon dioxide (CO2) into methane gas for energy use are a step closer after scientists discovered how bacteria make a component that facilitates the process. New ways to convert carbon dioxide (CO2) into methane gas for energy use are a step closer after scientists discovered how bacteria make a component that facilitates the process. Recycling CO2 into energy has immense potential for making these emissions useful rather than a major factor in global warming. However, because the bacteria that can convert CO2 into methane, methanogens, are notoriously difficult to grow, their use in gas production remains limited. This challenge inspired a team of scientists led by Professor Martin Warren, of the University of Kent's School of Biosciences, to investigate how a key molecule, coenzyme F430, is made in these bacteria. Although F430 - the catalyst for the production process - is structurally very similar to the red pigment found in red blood cells (haem) and the green pigment found in plants (chlorophyll), the properties of this bright yellow coenzyme allow methanogenic bacteria to breathe in carbon dioxide and exhale methane. By understanding how essential components of the process of biological methane production, methanogenesis, such as coenzyme F430 are made scientists are one step closer to being able to engineer a more effective and obliging methane-producing bacterium. This research is a collaboration between laboratories in Kent, Germany, Manchester and Durham. The results are now published in the journal Nature. For further information or interview requests contact Sandy Fleming at the University of Kent Press Office. News releases can also be found at http://www. The research teams have shown that coenzyme F430 is made from the same starting molecular template from which haem and chlorophyll are derived, but uses a different suite of enzymes to convert this starting material into F430. Key to this process is the insertion of a metal ion, which is glued into the centre of the coenzyme. If the process of biological methane production (methanogenesis) could be engineered into bacteria that are easier to grow, such as the microbe E. coli, then engineered strains could be employed to catch carbon dioxide emissions and convert them into methane for energy production. Established in 1965, the University of Kent - the UK's European university - now has almost 20,000 students across campuses or study centres at Canterbury, Medway, Tonbridge, Brussels, Paris, Athens and Rome. It has been ranked: 23rd in the Guardian University Guide 2017; 23rd in the Times and Sunday Times University Guide 2017; and 23rd in the Complete University Guide 2017. In the Times Higher Education (THE) World University Rankings 2015-16, Kent is in the top 10% of the world's leading universities for international outlook and 66th in its table of the most international universities in the world. The THE also ranked the University as 20th in its 'Table of Tables' 2016. Kent is ranked 17th in the UK for research intensity (REF 2014). It has world-leading research in all subjects and 97% of its research is deemed by the REF to be of international quality. In the National Student Survey 2016, Kent achieved the fourth highest score for overall student satisfaction, out of all publicly funded, multi-faculty universities. Along with the universities of East Anglia and Essex, Kent is a member of the Eastern Arc Research Consortium. The University is worth £0.7 billion to the economy of the south east and supports more than 7,800 jobs in the region. Student off-campus spend contributes £293.3m and 2,532 full-time-equivalent jobs to those totals. In 2014, Kent received its second Queen's Anniversary Prize for Higher and Further Education.


News Article | February 20, 2017
Site: phys.org

Researchers at The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) have designed a virus-like nanoparticle (VNP) that delivers drugs directly to the cells where they are needed. The lead author of a paper on the topic, Dr Frank Sainsbury, said the VNP was made from the structural proteins that formed the virus's protective shell. "Viruses have evolved to contain and protect bioactive molecules," Dr Sainsbury said. "They've also evolved smart ways to get into cells and deliver these bioactive molecules. "The VNP is an empty shell. It looks like a virus but it's not infectious. This makes it safe to use as a targeted drug delivery system." With infectious viral genes removed, empty shells can be loaded with small molecules or proteins resulting in a stable, well-protected therapeutic package. The outside of the shell then determines where the package will go. The ability to send drugs directly to their target is a critical goal in the development of safe, effective therapeutics. Currently many drugs, including anti-cancer chemotherapies, must be administered at high doses in order to have a therapeutic effect. This can lead to harsh side effects because drugs can damage healthy cells as well as intended targets. Dr Sainsbury and his colleagues developed a VNP using the Bluetongue virus, which normally infects cows, sheep and other ruminants. They picked the virus because of its stable shell, made of hundreds of proteins that are known to bind to a molecule found in high levels around many cancer cells. Dr Sainsbury teamed up with Dr Michael Landsberg at UQ's School of Chemistry and Molecular Biosciences and researchers at the Institute for Molecular Bioscience and the UK's John Innes Centre. They were able to demonstrate that the porous VNPs could be filled with small molecules for drug delivery and it also was possible to design VNPs to contain larger molecules, such as therapeutic proteins. Importantly, the researchers showed VNPs were able to bind to breast cancer cells, and then be absorbed. Dr Sainsbury said the next step was to load the VNPs with anti-cancer drugs and see if they could kill cancer cells without harming healthy cells. Although VNPs are highly complex and difficult to synthesise, Dr Sainsbury said they could be easily produced in the leaves of Nicotiana benthamiana, a wild relative of tobacco. By providing plant cells with genetic instructions for making VNPs, the plant was able to assemble virus protein shells without any permanent change to the plant's own genetic code. Dr Sainsbury said one day greenhouses may be able to produce large amounts of the nanoparticles within days. "This research unlocks a myriad of potential applications in therapeutic delivery," Dr Sainsbury said. Because the nanoparticles they have designed are highly stable, the AIBN research team is exploring other biotechnology applications. Explore further: Plant-made virus shells could deliver drugs directly to cancer cells


News Article | February 15, 2017
Site: cen.acs.org

University of California, Berkeley, scientists have found entirely new classes of Cas proteins, the enzymes responsible for snipping DNA in the CRISPR gene-editing system. The discovery expands the ever-growing CRISPR toolbox and creates a new wrinkle in the ongoing patent dispute between Berkeley and the Broad Institute of Harvard University and MIT over the gene-editing technology. Jillian F. Banfield led the Berkeley team, which scoured 155 million genes from microbes that cannot be grown in labs to find the Cas proteins. These microbes live in places as varied as groundwater, acidic drainage from mines, and the intestines of infants. In addition to finding new versions of traditional Cas9 proteins, the researchers discovered entirely new classes of Cas enzymes, dubbed CasX and CasY (Nature 2016, DOI: 10.1038/nature21059). Because Cas proteins are large, it’s challenging to deliver them into cells for gene-editing purposes. The newly discovered CasX enzymes, however, are among the smallest Cas proteins known, potentially a key advantage over other Cas variants, including the Cas9 class of protein that’s used by almost everyone working with CRISPR today. Cas9 is part of microbial immune systems found in the pathogenic Streptococcus pyogenes and many other species. “There is just an incredible diversity of microbial life out there,” Banfield says. And the CasX and CasY discovery “is a beautiful example of the kinds of valuable things that can be found.” Banfield partnered with Jennifer A. Doudna’s lab at UC Berkeley to demonstrate CasX and CasY’s potential for gene-editing in bacterial cells. Doudna, a cocreator of the CRISPR/Cas tool along with Max Planck Institute for Infection Biology’s Emmanuelle M. Charpentier, is currently embroiled in a patent dispute with the Broad Institute over who holds the licenses to CRISPR systems that use Cas9. The Berkeley researchers recently filed a patent application related to the newly reported CasX and CasY enzymes. Because these variants are different enough from Cas9, they could give Doudna and colleagues a cushion if they lose the ongoing patent fight. The timing of the Berkeley team’s Nature report on CasX and CasY is impeccable. The week before it was published, several companies, including CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences—which are all tied to either Doudna or Charpentier—formalized an alliance to share, protect, and enforce their intellectual property. The Broad-associated Editas Medicine quickly retaliated and announced its own agreement with five universities, licensing “advanced forms of Cas9,” as well as a previously reported Cas9 alternative enzyme named Cpf1. Jacob S. Sherkow of New York Law School says that in retrospect, knowledge of CasX and CasY likely fueled the cross-licensing agreements. “That is the piece of the jigsaw puzzle we were missing” when the deals took place, Sherkow says. “It cannot be coincidence.” “It is possible that all of the companies involved in CRISPR technologies could avoid being ‘losers’ in the patent dispute by just using different versions” of Cas proteins, says Knut J. Egelie of the Norwegian University of Science & Technology. Alternatives to Cas9 “will level out the game and make the patent interference decision less important,” he adds. Banfield says her lab will continue exploring the mysterious genomes of difficult-to-cultivate microbes, while Doudna’s group will carry out gene-editing tests with the new enzymes in cells beyond bacteria. This article has been translated into Spanish by Divulgame.org and can be found here.


PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced that the National Institutes of Health Blueprint Neurotherapeutics Network has awarded the company a grant under the Small Business Innovation Research (SBIR) program to advance novel treatments for epilepsy. Terms of the grant provide the potential for up to $2.5 million of direct support based on milestone attainment. The award supports Knopp’s preclinical and clinical development of small-molecule drug candidates directed to a validated, anti-seizure pharmaceutical target known as Kv7.2. Knopp expects initially to advance novel Kv7 activators in neonatal epileptic encephalopathy associated with a rare mutation in the KCNQ2 gene. These mutations cause severe epilepsy and profound developmental disability in newborns and infants, for whom conventional anti-seizure medications are insufficient or ineffective. Steven Dworetzky, PhD., Knopp’s Chief Scientific Officer and the Principal Investigator in the Blueprint-funded project, is a longtime Kv7 researcher whose group first cloned the Kv7.2 gene during his former tenure with the Bristol-Myers Squibb Co. “ This award comes not just with significant direct support but with access to top collaborators in the Blueprint Neurotherapeutics Network, who are committed to the discovery of disease-modifying treatments for the underlying causes of epilepsy,” he said. “ We already see evidence that our Blueprint collaboration will accelerate our move into human studies in challenging indications, including KCNQ2 encephalopathy and treatment-resistant, generalized epilepsy syndromes.” Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need in clearly defined patient populations. Our clinical-stage small molecule, dexpramipexole, will be entering Phase 2/3 clinical studies in hypereosinophilic syndromes and Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene. For more information, see www.knoppbio.com. Knopp’s Kv7 research is supported under Award Number U44NS093160 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH. This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs for dexpramipexole. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.


News Article | February 22, 2017
Site: www.businesswire.com

DES MOINES, Iowa & DAVIS, Calif.--(BUSINESS WIRE)--Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd., NASDAQ: SEED), an agricultural biotechnology trait and seed provider, and Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a California-based company that develops and commercializes agricultural productivity traits and nutritional products, today announced their collaboration to achieve the first-ever export of a key corn biotechnology product developed in China to the United States for completion of global regulatory trials. The successful movement of this corn seed, containing an insect resistance/herbicide tolerance trait discovered and developed in China, to the Arcadia greenhouse represents a key milestone in Origin’s strategic business plan to achieve global regulatory approvals for cultivation and international grain movement. “ This first-of-its-kind export validates Origin’s leading position in China biotech and its close alignment with Chinese ministries leading the transformation of the domestic seed industry. Combining Origin’s robust pipeline of value-added Chinese traits and elite corn germplasm with Arcadia’s research and development infrastructure demonstrates our plan to capture a sizeable piece of China’s estimated billion-dollar corn seed trait market,” said Bill Niebur, Origin chief executive officer. “ As a leader in agtech focused on modernizing the traditional corn seed market, our international team remains focused on accelerating research and development to improve the lives of Chinese farmers.” Arcadia and Origin signed an agreement under which Arcadia will assist Origin in developing information for submission to regulatory authorities in the U.S., China and other countries for the approval of their traits in corn. This project involves production of inbred and hybrid seed lines under quarantine conditions in Arcadia greenhouses. “ Arcadia has the proven expertise to bring traits through the regulatory process successfully and efficiently,” said Raj Ketkar, Arcadia’s president and CEO. “ We have conducted hundreds of studies in the laboratory, greenhouse and field to gain regulatory approvals for various traits in major crops, and we have a strong regulatory team that has developed complete regulatory dossiers in multiple countries. This collaboration with Origin is an example of how our partners can leverage these capabilities to accelerate the commercialization of novel ag biotech traits.” “ Ultimately, this milestone achievement will create more choices and opportunities for farmers,” said Jihong Liang, Origin chief technology officer. “ This is an important achievement, showcasing Origin’s competitive advantage in science and global reach through collaborations inside China and beyond its borders. Origin is leading the way in gaining regulatory approvals for this critical advanced technology globally to drive future business growth.” Origin’s investment and focus aligns tightly with China’s 13th Five Year Plan, which calls for the modernization of agriculture as the foundation for building a prosperous society. The Chinese government, including the Ministry of Agriculture (MOA) and Chinese Academy of Agricultural Sciences (CAAS), has advanced a policy vision to facilitate seed industry innovation, improve the competitiveness of the Chinese ag tech industry and cultivate new seed varieties for farmers around the world. Through these actions, China has shown strong commitment to advancing its ag industry through new advances in biotechnology. Origin anticipates China commercialization of corn biotechnology at the end of this decade. Origin Agritech Limited, founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, is China’s leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of crop seed biotechnologies, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Origin operates production centers, processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please visit the Company’s website at: http://www.originseed.com.cn or http://www.originseed.com.cn/en/. Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit www.arcadiabio.com. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company's intellectual property rights; and successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.


News Article | February 22, 2017
Site: en.prnasia.com

Insect resistant corn seed trait targeted at an estimated $1 billion marketDES MOINES, Iowa, Feb. 22, 2017 /PRNewswire/ -- Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd.) (NASDAQ: SEED), an agricultural biotechnology trait and seed provider, and Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a California-based company that develops and commercializes agricultural productivity traits and nutritional products, today announced their collaboration to achieve the first-ever export of a key corn biotechnology product developed in China to the United States for completion of global regulatory trials. The successful movement of this corn seed, containing an insect resistance/herbicide tolerance trait discovered and developed in China, to the Arcadia greenhouse represents a key milestone in Origin's strategic business plan to achieve global regulatory approvals for cultivation and international grain movement. "This first-of-its-kind export validates Origin's leading position in China biotech and its close alignment with Chinese ministries leading the transformation of the domestic seed industry. Combining Origin's robust pipeline of value-added Chinese traits and elite corn germplasm with Arcadia's research and development infrastructure demonstrates our plan to capture a sizeable piece of China's estimated billion-dollar corn seed trait market," said Bill Niebur, Origin chief executive officer. "As a leader in agtech focused on modernizing the traditional corn seed market, our international team remains focused on accelerating research and development to improve the lives of Chinese farmers." Arcadia and Origin signed an agreement under which Arcadia will assist Origin in developing information for submission to regulatory authorities in the U.S., China and other countries for the approval of their traits in corn. This project involves production of inbred and hybrid seed lines under quarantine conditions in Arcadia greenhouses. "Arcadia has the proven expertise to bring traits through the regulatory process successfully and efficiently," said Raj Ketkar, Arcadia's president and CEO. "We have conducted hundreds of studies in the laboratory, greenhouse and field to gain regulatory approvals for various traits in major crops, and we have a strong regulatory team that has developed complete regulatory dossiers in multiple countries. This collaboration with Origin is an example of how our partners can leverage these capabilities to accelerate the commercialization of novel ag biotech traits." "Ultimately, this milestone achievement will create more choices and opportunities for farmers," said Jihong Liang, Origin chief technology officer. "This is an important achievement, showcasing Origin's competitive advantage in science and global reach through collaborations inside China and beyond its borders. Origin is leading the way in gaining regulatory approvals for this critical advanced technology globally to drive future business growth." Origin's investment and focus aligns tightly with China's 13th Five Year Plan, which calls for the modernization of agriculture as the foundation for building a prosperous society. The Chinese government, including the Ministry of Agriculture (MOA) and Chinese Academy of Agricultural Sciences (CAAS), has advanced a policy vision to facilitate seed industry innovation, improve the competitiveness of the Chinese ag tech industry and cultivate new seed varieties for farmers around the world. Through these actions, China has shown strong commitment to advancing its ag industry through new advances in biotechnology. Origin anticipates China commercialization of corn biotechnology at the end of this decade. Origin Agritech Limited, founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, is China's leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of crop seed biotechnologies, Origin Agritech's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Origin operates production centers, processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please visit the Company's website at: http://www.originseed.com.cn or http://www.originseed.com.cn/en/. Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia's agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia's nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit www.arcadiabio.com. This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company's intellectual property rights; and successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/origin-arcadia-announce-china-biotechnology-collaboration-in-corn-300411337.html


News Article | February 15, 2017
Site: www.prweb.com

DuPont Industrial Biosciences announces that its renewably sourced fiber, DuPont™ Sorona®, has been recognized as a runner-up for Fiber Producer of the Year by the World Textile Awards. The first independent global awards competition, the World Textile Awards, are dedicated to recognizing and rewarding excellence across the global textile industry. Companies were assessed on their market position, technical performance, environmental and sustainability practices, quality control and employee programs. “Sorona® is an illustration of DuPont Industrial Biosciences’ commitment to developing and delivering exceptional products that benefit every level of the supply chain,” said Renee Henze, global marketing manager, DuPont Biomaterials. “This honor underscores the combination of eco-innovation, performance and function by Sorona® that can truly transform the textile industry and play a critical role in reducing its environmental footprint, without compromising on product quality.” Sorona® is derived, in part, from renewably sourced plant-based ingredients, allowing for a decreased dependence on fossil fuels and reduction in greenhouse gas emissions. In addition to sustainability, it offers unique performance benefits including: superior softness, unmatched durability and inherent stain resistance without the need for topical treatments. As a multipurpose fiber, it can be used alone or combined with synthetic or natural fibers for different benefits and endless options. Sorona® is one of the first 11 products approved to use the United States Department of Agriculture (USDA) new product label on certified bio-based products. It also received OEKO-TEX® Standard 100 Certification, the most stringent Class 1 certification. DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com. The DuPont Oval logo, DuPont™ Sorona® and the Sorona® logo are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates.


SAN FRANCISCO, Feb. 27, 2017 /PRNewswire/ -- Fluxion Biosciences announced today that Genetracer Biotech of Santander, Spain has been appointed as a Certified Service Provider for Fluxion's IsoFlux CTC Liquid Biopsy System. The IsoFlux system will be used in Genetracer Biotech's novel...


News Article | March 1, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that Franz Hefti, Ph.D., president and chief executive officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 1:30 p.m. ET in Boston. Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins. The broad applicability of the Proclara technology enables the company to target multiple protein misfolding diseases, including neurodegenerative diseases and several rare systemic amyloidoses. The lead GAIM drug candidate, NPT088, is in clinical development for the treatment of Alzheimer’s disease. For more information, please visit proclarabio.com.


LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces its post-earnings coverage on Becton, Dickinson and Co. (NYSE: BDX) ("BD"). The Company reported its first quarter fiscal 2017 financial results for the fourth quarter and fiscal on February 01, 2017. The medical technology firm surpassed top- and bottom-line expectation and raised its earnings outlook. Register with us now for your free membership at: One of Becton, Dickinson and Co.'s competitors within the Medical Instruments & Supplies space, The Cooper Companies, Inc. (NYSE: COO), announced on February 01, 2017, that it will release its Q1 2017 financial results on Thursday, March 02, 2017, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. AWS will be initiating a research report on Cooper Cos. a few days following its earnings release. Today, AWS is promoting its earnings coverage on BDX; touching on COO. Get our free coverage by signing up to: For the first fiscal quarter ended December 31, 2016, BD reported quarterly revenues of $2.922 billion, down 2.1% from the prior-year same period revenues, due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, the reported quarter revenues grew 6.1%. BD's revenue figures surpassed analysts' consensus of $2.85 billion. On a performance basis, BD's gross profit margin improved by 190 basis points compared to the year ago same quarter at 54.3%. This growth was driven by continuous improvement initiatives, cost synergies, and favorable mix which include the positive impact of divestitures. On an operating margin basis, the Company delivered an approximately 250 basis points of margin expansion to 23.8%, as it continues to drive cost synergies. In addition, margin expansion was positively impacted by the divestiture of the respiratory solutions business. For Q1 FY17, BD's diluted earnings per share were $2.58 compared to $1.06 in the prior-year comparable period. This represents an increase of 143.4% and is primarily due to a litigation reserve reversal following a favorable appellate antitrust ruling. The Company's adjusted diluted earnings per share were $2.33 in the reported quarter compared to $1.96 in the prior-year same period. This represents an increase in adjusted diluted earnings per share of 18.9%, or 19.4% on a currency-neutral basis. The earning numbers comfortably surpassed Wall Street's expectations of $2.12 per share. During Q1 FY17, in the BD's Medical segment, worldwide revenues totaled $1.964 billion down 4.4% from Q1 FY16 due to the divestiture of the Respiratory Solutions business. On a comparable, currency-neutral basis, revenues increased 7.5%. Performance in the Pharmaceutical Systems and Medication Management Solutions units was positively impacted, in part, by the timing of customer orders and capital placements, respectively, which occurred in Q1 FY17, earlier than the Company initially anticipated. In the BD Life Sciences segment, worldwide revenues for Q1 FY17 were $958 million, an increase of 2.7% over the prior-year comparable period, or an increase of 3.2% on a currency-neutral basis. The segment's revenue growth reflects strong performance in the Diagnostic Systems and Preanalytical Systems units. For Q1 FY17, BD's revenue in the US was $1.63 billion, a decrease of 3.6% from the prior-year same period due to the aforementioned divestiture. On a comparable basis, US revenues increased 5.5%. Within BD's Medical segment, growth was driven by strong performance in the Medication Management Solutions and Diabetes Care units. Growth in BD's Life Sciences segment was driven by solid growth in the Diagnostics Systems unit, and favorable timing of orders in Advanced Bioprocessing in the Biosciences unit. For Q1 FY17, BD's revenues outside of the US of $1.292 billion were about flat when compared with the prior year corresponding period due to the aforementioned divestiture. On a comparable, currency-neutral basis, revenues outside of the US increased 6.8%. For the international region within BD's Medical segment, growth was driven by capital installations in the Medication Management Solutions unit, and strength in the Pharmaceutical Systems unit, which was aided in part by the aforementioned timing of customer orders. Growth in BD's Life Sciences segment reflects sales of safety-engineered products, and strength in Latin America and Asia/Pacific in the Diagnostic Systems unit, including a favorable comparison to the prior-year's same period in China. BD expects FY17 revenues to decrease 3.5% to 4.0%, down compared to the previously issued guidance of a decrease of 3.0% to 3.5% due to the incrementally negative estimated impact from foreign currency. The Company continues to estimate that revenues for FY17 will increase 4.5% to 5.0% on a comparable, currency-neutral basis. The Company now expects FY17 diluted earnings per share to be between $7.90 and $8.00, which represents growth of approximately 76.0% to 78.0%. On a currency-neutral basis, the Company is raising FY17 adjusted diluted earnings per share to $9.70 to $9.80, which represents growth of 13.0% to 14.0% including an estimated 1.5% of dilution related to the Respiratory Solutions divestiture. This is an increase from previously issued guidance of $9.62 to $9.72, which represented approximately 12.0% to 13.0 % growth. On February 15, 2017, Becton, Dickinson and Co.'s share price finished the trading session at $180.09, slightly advancing 0.74%. A total volume of 855.05 thousand shares exchanged hands. The stock has advanced 3.85% and 27.05% in the last month and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have gained 8.78%. The stock is trading at a PE ratio of 29.93 and has a dividend yield of 1.62%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces its post-earnings coverage on Becton, Dickinson and Co. (NYSE: BDX) ("BD"). The Company reported its first quarter fiscal 2017 financial results for the fourth quarter and fiscal on February 01, 2017. The medical technology firm surpassed top- and bottom-line expectation and raised its earnings outlook. Register with us now for your free membership at: One of Becton, Dickinson and Co.'s competitors within the Medical Instruments & Supplies space, The Cooper Companies, Inc. (NYSE: COO), announced on February 01, 2017, that it will release its Q1 2017 financial results on Thursday, March 02, 2017, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. AWS will be initiating a research report on Cooper Cos. a few days following its earnings release. Today, AWS is promoting its earnings coverage on BDX; touching on COO. Get our free coverage by signing up to: For the first fiscal quarter ended December 31, 2016, BD reported quarterly revenues of $2.922 billion, down 2.1% from the prior-year same period revenues, due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, the reported quarter revenues grew 6.1%. BD's revenue figures surpassed analysts' consensus of $2.85 billion. On a performance basis, BD's gross profit margin improved by 190 basis points compared to the year ago same quarter at 54.3%. This growth was driven by continuous improvement initiatives, cost synergies, and favorable mix which include the positive impact of divestitures. On an operating margin basis, the Company delivered an approximately 250 basis points of margin expansion to 23.8%, as it continues to drive cost synergies. In addition, margin expansion was positively impacted by the divestiture of the respiratory solutions business. For Q1 FY17, BD's diluted earnings per share were $2.58 compared to $1.06 in the prior-year comparable period. This represents an increase of 143.4% and is primarily due to a litigation reserve reversal following a favorable appellate antitrust ruling. The Company's adjusted diluted earnings per share were $2.33 in the reported quarter compared to $1.96 in the prior-year same period. This represents an increase in adjusted diluted earnings per share of 18.9%, or 19.4% on a currency-neutral basis. The earning numbers comfortably surpassed Wall Street's expectations of $2.12 per share. During Q1 FY17, in the BD's Medical segment, worldwide revenues totaled $1.964 billion down 4.4% from Q1 FY16 due to the divestiture of the Respiratory Solutions business. On a comparable, currency-neutral basis, revenues increased 7.5%. Performance in the Pharmaceutical Systems and Medication Management Solutions units was positively impacted, in part, by the timing of customer orders and capital placements, respectively, which occurred in Q1 FY17, earlier than the Company initially anticipated. In the BD Life Sciences segment, worldwide revenues for Q1 FY17 were $958 million, an increase of 2.7% over the prior-year comparable period, or an increase of 3.2% on a currency-neutral basis. The segment's revenue growth reflects strong performance in the Diagnostic Systems and Preanalytical Systems units. For Q1 FY17, BD's revenue in the US was $1.63 billion, a decrease of 3.6% from the prior-year same period due to the aforementioned divestiture. On a comparable basis, US revenues increased 5.5%. Within BD's Medical segment, growth was driven by strong performance in the Medication Management Solutions and Diabetes Care units. Growth in BD's Life Sciences segment was driven by solid growth in the Diagnostics Systems unit, and favorable timing of orders in Advanced Bioprocessing in the Biosciences unit. For Q1 FY17, BD's revenues outside of the US of $1.292 billion were about flat when compared with the prior year corresponding period due to the aforementioned divestiture. On a comparable, currency-neutral basis, revenues outside of the US increased 6.8%. For the international region within BD's Medical segment, growth was driven by capital installations in the Medication Management Solutions unit, and strength in the Pharmaceutical Systems unit, which was aided in part by the aforementioned timing of customer orders. Growth in BD's Life Sciences segment reflects sales of safety-engineered products, and strength in Latin America and Asia/Pacific in the Diagnostic Systems unit, including a favorable comparison to the prior-year's same period in China. BD expects FY17 revenues to decrease 3.5% to 4.0%, down compared to the previously issued guidance of a decrease of 3.0% to 3.5% due to the incrementally negative estimated impact from foreign currency. The Company continues to estimate that revenues for FY17 will increase 4.5% to 5.0% on a comparable, currency-neutral basis. The Company now expects FY17 diluted earnings per share to be between $7.90 and $8.00, which represents growth of approximately 76.0% to 78.0%. On a currency-neutral basis, the Company is raising FY17 adjusted diluted earnings per share to $9.70 to $9.80, which represents growth of 13.0% to 14.0% including an estimated 1.5% of dilution related to the Respiratory Solutions divestiture. This is an increase from previously issued guidance of $9.62 to $9.72, which represented approximately 12.0% to 13.0 % growth. On February 15, 2017, Becton, Dickinson and Co.'s share price finished the trading session at $180.09, slightly advancing 0.74%. A total volume of 855.05 thousand shares exchanged hands. The stock has advanced 3.85% and 27.05% in the last month and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have gained 8.78%. The stock is trading at a PE ratio of 29.93 and has a dividend yield of 1.62%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Loading Biosciences collaborators
Loading Biosciences collaborators